Interní Med. 2005; 7(4): 167-169

Facilitated primary percutaneous coronary intervention - the current view

MUDr. Pavel Boček
I. Interní klinika, kardiologické oddělení, FN Plzeň

The treatment of acute ST segment elevation myocardial infarction (STEMI) passed through important development concentrated on prognostic impact of the patients during last 20 years. Primary percutaneous coronary intervention (pPCI) became the method of the choice in this situation. Nowadays the possibility how to combine the advantage of immediately accessible fibrinolytic therapy and PCI provided immediately after transportation of the patient to the PCI centre is searched for. This approach is named facilitated PCI. The principal idea is that as earlier the flow in the infarct related artery is restored, as better prognosis of the patients. As well implantation of the stent into the infarct related artery even if the flow after fibrinolytic therapy is good improves the prognosis of the patients. This is why they are trying to combine the early PCI with fibrinolytic application or treatment by glycoprotein IIb/IIIa receptor antagonists or combination of both before the transport to the PCI centre. The results of smaller studies or of those, which were not primary orientated on this problem seem to be promising, but before the definitive decision if, when and to whom to indicate facilitation and by which pharmacological agent we must wait for the results of large randomised studies, of which the primary aim is the facilitation of PCI.

Keywords: Key words: acute coronary syndrome, direct percutaneous coronary intervention, fibrinolytic treatment.

Published: January 1, 2006  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Boček P. Facilitated primary percutaneous coronary intervention - the current view. Interní Med. 2005;7(4):167-169.
Download citation

References

  1. Andersen HR, Nielsen TT, Rasmussen K, et al. A comparison of coronary angioplasty with fibrinolytic therapy in acute myocardial infarction. N Engl J Med 2003; 349: 733-742. Go to original source... Go to PubMed...
  2. Antman E, MGiugliano RP, Gibson CM, McCabe CH, Coussement P, Kleiman NS, Vahanian A, Adgey AAJ, Menown I, Rupprecht H-J, Van der Wieken R, Ducas J, Scherer J, Anderson K,Van de Werf F, Braunwald E, for the TIMI 14 Investigators. Abciximab Facilitates the Rate and Extent of Thrombolysis - Results of the Thrombolysis In Myocardial Infarction (TIMI) 14 Trial. Circulation 1999; 99: 2720-2732. Go to original source... Go to PubMed...
  3. Dalby M, Bouzamondo A, Lechat P, Montalescot G. Transfer for primary angioplasty versus immediate thrombolysis in acute myocardial infarction: a meta-analysis. Circulation 2003; 108: 1809-1814. Go to original source... Go to PubMed...
  4. Fernandez-Avilés F, Alonso JJ, Castro-Beiras A, Vázquez N, Blanco J, Alonso-Briales J, López-Mesa J, FernándezVazquez F, Calvo I, Martínez-Elbal L, San Román JA, Ramos B. Routine invasive strategy within 24 hours of thrombolysis versus ischaemia-guided conservative approach for acute myocardial infarction with ST-segment elevation (GRACIA-1): a randomised controlled trial. Lancet 2004; 364: 1045-1053. Go to original source... Go to PubMed...
  5. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group: Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet 1994; 343: 311-322. Go to original source...
  6. Gibson CM, Cannon ChP, Murphy SA, Marble SJ, Barron HV, Braunwald E, for the TIMI Study Group. Relationship of the TIMI Myocardial Perfusion Grades, Flow Grades, Frame Count, and Percutaneous Coronary Intervention to Long-Term Outcomes After Thrombolytic Administration in Acute Myocardial Infarction. Circulation. 2002; 105: 1909. Go to original source... Go to PubMed...
  7. Gibson CM, Karha J, Murphy SA, James D, Morrow DA, Cannon ChP, Giugliano RP, Antman EM, Braunwald E and TIMI Study Group. Early and long-term clinical outcomes associated with reinfarction following fibrinolytic administration in the thrombolysis in myocardial infarction trials. JACC; 42: 7-16. Go to PubMed...
  8. Gibson CM, Murphy SA; Rizzo MJ, Ryan KA, Marble SJ, McCabe CH, Cannon ChP; Van de Werf F. Eugene Braunwald. Relationship Between TIMI Frame Count and Clinical Outcomes After Thrombolytic Administration. Circulation 1999; 99: 1945-1950. Go to original source... Go to PubMed...
  9. Gore JM, Granger ChB, Simoons ML, Sloan MA, Weaver WD, White HD, Barbash GI, Van de Werf F, Aylward PE, Topol EJ, and R.M. Califf Stroke After Thrombolysis: Mortality and Functional Outcomes in the GUSTO-I Trial. Circulation 1995; 92: 2811-2818. Go to original source... Go to PubMed...
  10. Kastrati A, Mehilli J, Schlotterbeck K, et al., for the BRAVE Investigators. A randomized evaluation of early administration of reteplase plus abciximab or abciximab alone prior to percutaneous coronary intervention in patients with acute myocardial infarction. JAMA 2004; 291: 947-954. Go to original source... Go to PubMed...
  11. Lenderink T, Simoons ML, Van Es GA, Van de Werf F, Verstraete M, and A.E.R. Arnold. Benefit of Thrombolytic Therapy Is Sustained Throughout Five Years and Is Related to TIMI Perfusion Grade 3 But Not Grade 2 Flow at Discharge. Circulation 1995; 92: 1110-1116. Go to original source... Go to PubMed...
  12. Maroko PR, Kjekshus JK, Sobel BE, Watanabe T, Covell JW, Ross J Jr, and E Braunwald: Factors influencing infarct size following experimental coronary artery occlusions. Circulation 1971; 43: 67-82. Go to original source... Go to PubMed...
  13. Montalescott G, Barragan P, Wittenberg O, Ecollan P, Elhaded S, et al., for the ADMIRAL investigators. Platelete glykoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med 2001; 344: 1895-1903. Go to original source... Go to PubMed...
  14. Ohman EM, RM Califf, EJ Topol, R Candela, C Abbottsmith, S Ellis, KN Sigmon, D Kereiakes, B George, and R Stack. Consequences of reocclusion after successful reperfusion therapy in acute myocardial infarction. TAMI Study Group. Circulation 1990; 82: 781-791. Go to original source... Go to PubMed...
  15. Ross AM, Coyne KS, Reiner JS, Greenhouse SW, Fink C, Frey A, Moreyra E, Traboulsi M, Racine N, Riba AL, et al. A randomized trial comparing primary angioplasty with a strategy of short-acting thrombolysis and immediate planned rescue angioplasty in acute myocardial infarction: the PACT trial. JACC 1999; 34: 1954-1962. Go to original source... Go to PubMed...
  16. Ryan TJ, et al. Update: ACC/AHA Guidelines for the Management of Patients With Acute Myocardial Infarction A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction) JACC 34, 1999; No. 3: 890-911.
  17. Schomig A, Ndrepepa G, Mehilli J, et al. Therapy-dependent influence of time-to-treatment interval on myocardial salvage in patients with acute myocardial infarction treated with coronary artery stenting or thrombolysis. Circulation 2003; 108: 1084-1088. Go to original source... Go to PubMed...
  18. Topol EJ. GUSTO V Investigators. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial. Lancet. 2001 Jun 16; 357(9272): 1905-1914. Go to original source... Go to PubMed...
  19. van´t Hof AWJ, EN, et al. Facilitation of primary coronary angioplasty by early start of a glycoprotein 2b/3a inhibitor: results of the Ongoing Tirofiban in Myocardial infarction Evaluation (On-TIME) trial. Eur Heart J 2004; 25: 837-846. Go to original source... Go to PubMed...
  20. van de Werf F, Barron HV, Armstrong PW, Granger CB, Berioli S, Barbash G, Pehrsson K, Verheugt FW, Meyer J, Betriu A, Califf RM, Li X, Fox NL; ASSENT-2 Investigators. Assessment of the Safety and Efficacy of a New Thrombolytic. Incidence and predictors of bleeding events after fibrinolytic therapy with fibrin-specific agents: a comparison of TNK-tPA and rt-PA. Eur Heart J. 2001; 22 (24): 2221-2223. Go to original source... Go to PubMed...
  21. Widimsky P, Budesinsky T, Vorac D, et al. Long distance transport for primary angioplasty vs immediate thrombolysis in acute myocardial infarction: final results of the randomized national multicentre trial - PRAGUE-2. Eur Heart J 2003; 94-104. Go to original source... Go to PubMed...
  22. Zijlstra F. Angioplasty vs thrombolysis for acute myocardial infarction: a quantitative overview of the effects of interhospital transportation. Eur Heart J. 2003; 24: 21-23. Go to original source... Go to PubMed...




Internal Medicine for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.